Dai, Weili 4

What Happened

• Weili Dai, a director of Astrana Health, received an award of 4,525 restricted shares of the company's common stock on June 10, 2026. The shares were granted at $0.00 per share (no cash paid), so the reported acquisition value is $0. This transaction is reported on a Form 4 as an award/grant (transaction code A).
• The restricted shares were granted under Astrana Health’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the date of the company’s 2027 annual meeting of stockholders.

Key Details

• Transaction date: June 10, 2026; grant price: $0.00 per share (total cash paid $0).
• Vesting: 4,525 restricted shares vest on the earlier of June 10, 2027 or the 2027 annual meeting (per footnotes).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnotes: F1/F2 state these are restricted shares under the 2024 Equity Incentive Plan with the vesting schedule noted above.
• Filing timeliness: Form filed June 12, 2026 — appears to be timely (Form 4s are generally due within two business days of the transaction).

Context

• This is a compensation-related grant (restricted stock award) rather than an open-market purchase or sale. Such awards are common for directors and are subject to vesting; they align long-term interests but do not by themselves indicate immediate buying or selling intent.
• Retail investors should treat this as a routine director equity grant unless followed by additional trading activity (e.g., sales or option exercises) disclosed in later filings.